ABSI

AbsciF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$4.21

Analysis reference price unavailable

Analysis 2025-11-17 · RankAlpha Sentiment AI

Most likely

Base case

50%

Probability

Target price

$2.34

Analysis reference price unavailable

Analysis 2025-11-17 · RankAlpha Sentiment AI

B-

Bear case

25%

Probability

Target price

$1.17

Analysis reference price unavailable

Analysis 2025-11-17 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2025-11-17

AI commentary

Market sentiment is cautious-to-mixed: investors price in high binary risk from platform milestones and financing needs while some buyers speculate on licensing upside [#PR-2025-07-20], [#10-Q-2025-Q2p12]. Short-term volume spikes follow news releases, indicating event-driven trading rather than steady accumulation [#Market-2025-11].

RankAlpha Sentiment AI - 2025-11-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-03-31eventUpcoming clinical or partnership updates for protein-engineering platformHigh impact

Absci's platform and collaborations can produce binary updates (trial milestones, partner licensing deals) that materially move valuation; prior PRs and collaborator announcements were drivers of volatility [#PR-2025-04-15], [#10-Q-2025-Q2p3].

2026-06-30catalystCash runway / financing needHigh impact

Small-cap biotech with ongoing R&D spend faces dilution risk if cash runway shortens; a financing announcement or unexpected cash burn increase could depress share price [#10-Q-2025-Q2p12].

2026-12-31catalystCommercialization / licensing winHigh impact

A favorable licensing deal or initial commercialization of a discovery from Absci's platform could re-rate shares higher given limited current revenue [#PR-2025-07-20].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-17 • Updated nightlySource: Internal modelMethodology